A 5-day-old female neonate born to a 32-year-old mother via vaginal delivery presents with fever (38.8°C rectal), poor feeding, and irritability. Delivery was uncomplicated with no maternal fever or prolonged rupture of membranes. On examination, the baby is alert but has a petechial rash on the trunk and lower extremities. Heart rate is 170/min, respiratory rate 62/min, and blood pressure is 55/35 mmHg. Blood culture is positive for *Neisseria meningitidis*. Lumbar puncture shows CSF with 450 WBC/μL (90% neutrophils), protein 180 mg/dL, glucose 15 mg/dL (serum glucose 85 mg/dL), and Gram-negative diplococci. What is the most appropriate immediate management?

Explanation

## Clinical Diagnosis: Neonatal Meningitis due to *Neisseria meningitidis* **Key Point:** This is **confirmed bacterial meningitis** caused by *Neisseria meningitidis* in a 5-day-old neonate, presenting with fever, petechial rash, signs of sepsis, and CSF pleocytosis with markedly low glucose. ## CSF Findings Analysis | Parameter | Value | Interpretation | |---|---|---| | WBC | 450/μL | Pleocytosis (normal neonatal < 30) | | Differential | 90% neutrophils | Bacterial pattern | | Protein | 180 mg/dL | Elevated (normal < 100 mg/dL) | | Glucose | 15 mg/dL | Markedly low | | CSF:Serum glucose ratio | 15:85 = 0.18 | < 0.4 = bacterial meningitis | | Gram stain | Gram-negative diplococci | *Neisseria meningitidis* | ## Antibiotic Selection: Ceftriaxone for Neonatal Meningococcal Meningitis **High-Yield:** *Neisseria meningitidis* is highly susceptible to third-generation cephalosporins. For confirmed meningococcal meningitis, **ceftriaxone 80 mg/kg/day IV** (in two divided doses) is the **first-line recommended agent** per current guidelines (Nelson Textbook of Pediatrics 21e; AAP Red Book 2024; WHO meningitis guidelines): 1. **Superior bactericidal activity** against *N. meningitidis* with excellent CSF penetration 2. **Convenient dosing** (once or twice daily) reduces administration errors 3. **Cefotaxime** is an acceptable alternative but is not preferred over ceftriaxone for confirmed meningococcal disease in current evidence-based guidelines 4. The concern about biliary sludge/pseudolithiasis with ceftriaxone in neonates is **rare and clinically insignificant** in the context of life-threatening meningitis; it does not constitute a contraindication per AAP Red Book 2024 **Clinical Pearl:** Vancomycin is NOT indicated here because *N. meningitidis* is uniformly susceptible to penicillins and cephalosporins. Penicillin G alone has inferior CSF penetration compared to third-generation cephalosporins and is not the preferred agent for neonatal meningitis. ## Adjunctive Dexamethasone **Key Point:** Dexamethasone **0.15 mg/kg/dose IV Q6H for 4 days** is recommended as adjunctive therapy in bacterial meningitis (including meningococcal disease) because it: - Reduces neuroinflammation and cytokine-mediated injury - Decreases risk of **sensorineural hearing loss** (most well-established benefit) - Improves neurodevelopmental outcomes - **Timing:** Must be given **with or just before the first antibiotic dose** to be effective; post-antibiotic administration provides no benefit Per Nelson Textbook of Pediatrics and AAP Red Book 2024, dexamethasone adjunctive therapy is recommended for bacterial meningitis in children ≥6 weeks; its use in neonates < 6 weeks is less well-established but is widely practiced for confirmed meningococcal or pneumococcal meningitis given the severity of disease. ## Why Not Option C (Cefotaxime + Dexamethasone)? While cefotaxime is an acceptable alternative, **ceftriaxone is the preferred first-line agent** for confirmed meningococcal meningitis per current international guidelines. The claim that cefotaxime has superior CSF penetration over ceftriaxone in neonates is not supported by current evidence; both achieve adequate CSF concentrations. The biliary sludge concern with ceftriaxone is overstated and does not justify preferring cefotaxime in life-threatening meningitis. ## Why Not Option A (Penicillin G + Gentamicin)? Penicillin G has inferior CSF penetration compared to third-generation cephalosporins. Gentamicin adds nephrotoxicity risk without benefit for meningococcal disease. This combination is not recommended for neonatal meningitis. ## Why Not Option B (Vancomycin + Cefotaxime)? Vancomycin is reserved for penicillin-resistant *S. pneumoniae* or when the organism is unknown. Since *N. meningitidis* is confirmed and uniformly susceptible to cephalosporins, vancomycin adds no benefit and increases nephrotoxicity risk. [cite: Nelson Textbook of Pediatrics 21e Ch 102; AAP Red Book 2024; WHO Meningitis Management Guidelines]